Leaders from both organizations discuss the motivations behind and the goals of Informa Markets' deal to manage the HIMSS Global Health Conference and Exhibition.
Amir Bozorgzadeh, cofounder and CEO of Virtuleap, which combines neuroscience and virtual reality for brain training, discusses a partnership with Roche to screen for precursors of cognitive impairment.
Parkland Health SVP and CIO Joe Longo and SVP, Associate CMO and CMIO Dr. Brett Moran, describe their experiences working with Dallas County's health department to provide equitable care access during the COVID-19 pandemic.
Niall O'Connor, chief technology officer at Cohere Health, discusses how AI and machine learning can help streamline the prior authorization process by analyzing the totality of patient information and reducing denials by health plans.
Dr. Oscar Marroquin, chief healthcare data and analytics officer at UPMC, discusses clinical analytics' relationship with artificial intelligence, and the importance of understanding the foundational elements of using AI in healthcare.
HIMSS23 attendees discuss the conference post-pandemic, how attending helps explore new pathways for their company, and what technologies they look forward to learning about most on the exhibit floor.
Edward Yurcisin, chief technology officer at NCQA, tells how health plans and organizations can improve healthcare quality by utilizing open-source innovation between payers and providers and how NCQA works to help them achieve that goal.
Freddie Feldman, director of voice and conversational interfaces at Wolters Kluwer, talks about the potential of using AI and natural language processing for voice interfaces, and about limitations in the answers that generative AI can provide.
Lumeon Chief Growth Officer Greg Miller discusses reluctance in healthcare leaders to apply automation, but explains that the technology can take over manual, repetitive tasks for physicians while yielding more predictable and reliable outcomes.
Dr. Payel Das, principal research staff member and manager in the Trusted AI department of IBM, and an IBM master inventor, relays how using large language models that fill gaps in datasets may improve drug discovery in the future.
